Keral

Dexketoprofen, the active ingredient in Keral, is a nonsteroidal anti‑inflammatory drug (NSAID) presented as an injectable solution for intramuscular and intravenous use. It is indicated for the relief of mild to moderate pain, post‑operative pain and musculoskeletal pain in adult patients. GNH USA supplies Keral as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Dexketoprofen acts as an NSAID to manage pain and inflammation in several clinical settings.

Mild to moderate pain: provides rapid analgesia for acute pain conditions. Post‑operative pain: reduces discomfort following surgical procedures. Musculoskeletal pain: alleviates pain associated with muscle and joint disorders.

Adverse reactions may occur with dexketoprofen use and are categorized by frequency.

Common Side Effects: - Nausea - Dizziness - Headache - Injection‑site pain or erythema - Dyspepsia - Somnolence

Serious or Rare Side Effects: - Anaphylactic or severe allergic reactions - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Gastrointestinal bleeding or ulcer perforation - Hepatic dysfunction or elevated liver enzymes - Acute renal impairment - Cardiovascular events such as myocardial infarction or stroke

Before prescribing dexketoprofen, clinicians should consider several safety aspects.

Assess renal function: adjust use in patients with renal impairment. Monitor gastrointestinal risk: avoid in patients with active ulcers or bleeding. Avoid in known hypersensitivity: contraindicated for individuals allergic to dexketoprofen or other NSAIDs. Use caution in cardiovascular disease: evaluate thrombotic risk. Pregnancy and lactation: use only if clearly needed after risk assessment. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Dexketoprofen may interact with other medicines, requiring attention to avoid harmful effects.

Major Interactions (Avoid): - Anticoagulants (e.g., warfarin): increased bleeding risk. - Other NSAIDs or COX‑2 inhibitors: additive gastrointestinal toxicity. - Selective serotonin reuptake inhibitors (SSRIs): heightened bleeding risk. - Lithium: NSAIDs may raise lithium serum concentrations. - Methotrexate: reduced renal clearance leading to toxicity.

Moderate Interactions (Monitor Closely): - ACE inhibitors: possible decline in renal function. - Diuretics: risk of renal impairment when combined. - Corticosteroids: increased risk of gastrointestinal ulceration.